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ABSTRACT:
Despite recent advances in treatment, malignant pleural mesothelioma (MPM) 
remains a deadly disease. Targeted therapy generated broad interests and is highly 
expected for the treatment of MPM, yet promising preclinical results have not 
been translated into substantial clinical benefits for the patients. In this study, we 
tried to identify the genes which play functional roles in cell migration as well as 
to test whether they can be used as novel targets for molecular targeted therapy 
for MPM in preclinical model. In our study, pregnancy-associated plasma protein 
A (PAPPA) was identified as a gene whose expression level is correlated with MPM 
cell migration by correlation analysis combining MPM cell migration ability and their 
gene expression profiles. Highly migratory cells were selected from MPM cell lines, 
MSTO-211H, NCI-H290 and EHMES-1 in vitro and up-regulation of PAPPA in these 
cells were confirmed. In vitro, PAPPA was demonstrated to stimulate the MPM cell 
migration via cleavage of insulin-like growth factor-binding protein-4 and subsequent 
release of IGF-1. Gene silencing of PAPPA in MPM cells led to reduced migration, 
invasion and proliferation. Furthermore, PAPPA shRNA transfected NCI-H290 when 
orthotopically inoculated into pleural cavity of severe combined immunodeficiency 
recipient mice, failed to develop tumors and produce bloody pleural effusion as control 
shRNA transfected cells did. Our study suggests that PAPPA plays a functional role 
in promoting MPM cell migration and it might serve as a potential therapeutic target 
for the treatment of MPM.
INTRODUCTION
Malignant pleural mesothelioma (MPM), the most 
common mesothelioma, is an aggressive tumor associated 
with prior asbestos exposures that arise from mesothelial 
surface of pleura [1]. Despite recent advances in treatment, 
MPM remains a deadly disease. The benefit from 
surgery is confined to a minority of patients. In addition, 
cytotoxic chemotherapeutic drugs improve quality of 
life for unresectable patients, and can prolong survival, 
though only by a few months at best [2]. There has been 
substantial interest in the role of targeted agents in the 
treatment of MPM, a variety of them has been tested as 
therapy for this malignancy in preclinical studies [3-5], 
yet promising preclinical data has not been translated into 
clinical benefits in a significant way [6]. More about the 
biology of this disease might be needed for the molecular 
targeted therapy to yield promising new treatment options.
Even though metastases are rarely the cause of 
death of MPM patients, the unique clinical feature of local 
spread along tissue planes not only causes increasing pain 
and functional abnormalities, but also makes it a difficult 
neoplasm to manage [1, 7]. Cell migration as a key to 
local invasion, might provide an opening for therapeutic 
approaches if we can understand more about the molecular 
biology that underlie it [8]. The goal of our study was 
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to identify the genes which might be involved in the 
regulation of cell migration as well as to evaluate whether 
they can be used as targets for the inhibition of MPM cell 
migration, invasion or even tumor progression.
To achieve this goal, we investigated the migration 
ability of 8 human MPM cell lines in vitro and their gene 
expression profiles. Genes whose expressions correlated 
with cell migration were identified by correlation analysis 
combining the migration ability of MPM cells and their 
gene expression profiles. Among these genes, pregnancy-
associated plasma protein A (PAPPA) caught our attention. 
PAPPA, one of four proteins of placental origin found 
circulating at high concentrations in pregnant women [9], 
is now basically recognized as a local regulator of Insulin-
like growth factor 1 (IGF-1) bioavailability through 
cleavage of IGF-binding proteins (IGFBPs) [10-12]. The 
IGF axis was reported to be involved in the pathogenesis 
of many cancer types [13], including MPM [14-16], and 
therapeutics aimed at the IGF axis are under extensive 
clinical investigation [17]. Accumulating preclinical 
evidences support the idea that PAPPA may play a role in 
cancer [18-22].
In the present study, a series of in vitro assay was 
performed to try to reveal the mechanism of the migration-
promoting role of PAPPA. To further confirm the causal 
role of PAPPA in MPM cell migration, we applied both 
small interfering RNA (siRNA) and small hairpin RNA 
(shRNA) targeting PAPPA to investigate the silencing 
effects of PAPPA on MPM cell migration. Finally, we 
used an orthotopic xenograft mouse model of MPM [3-5, 
24] to evaluate the efficacy of PAPPA silencing on tumor 
development and progression in vivo.
RESULTS 
Expression of PAPPA is correlated with migration 
ability in MPM cell lines
To identify potential candidate genes whose function 
are related with MPM cell migration, we determined the 
migration ability of eight MPM cell lines using transwell 
chamber migration assay (Fig. 1A), and obtained their 
gene expression profiles using Affymetrix whole-genome 
oligonucleotide microarray (Supplementary Fig. 1A). 
After we applied Pearson’s correlation by combining 
the migration ability of MPM cell lines and their gene 
expression profiles, expression levels of several genes 
revealed relatively high correlations with MPM cell 
migration ability (Supplementary Fig. 1B). Among these 
genes, we focused on PAPPA, which encodes a secreted 
metalloproteinase that degrades inhibitory IGFBPs. We 
validated our microarray expression data for PAPPA with 
quantitative real time PCR (qRT-PCR) (Fig. 1B). Overall, 
PAPPA expression results generated from the two different 
techniques were well correlated (Supplementary Fig. 
1B), except that of NCI-H28. Thus we did not include 
NCI-H28 in the following studies. The similarity of 
expression levels of PAPPA obtained from microarray 
and qRT-PCR can also be extended to their correlations 
with MPM cell migration ability (Supplementary Fig. 1B, 
Fig. 1C). Considering that PAPPA functions as a secreted 
protein, we further determined the secreted protein levels 
of PAPPA in the conditioned medium (48 h) of MPM cell 
culture (Fig. 1D). The secreted PAPPA levels of MPM 
cell lines are also tend to be positively correlated with 
their migration ability (Fig. 1E, Pearson r = 0.7217, P = 
0.0671).
Considering the possibility that the correlation is 
simply due to coincidence, rather than the functional role 
of PAPPA in the regulation of MPM cell migration, we 
applied an in vitro selection strategy to further examine 
this correlation (Fig. 2A). Highly migratory MPM 
cells were selected, and their gene expression levels 
were examined. Three MPM cell lines, MSTO-211H, 
NCI-H290 and Y-MESO-14, after 3-5 round in vitro 
selection, increased their migration ability roughly 5-fold 
compared to their corresponding parental cell lines (Fig. 
2B). Interestingly, when analyzing their gene expression 
profiles with microarray, we found that the genes including 
PAPPA, which we previously identified whose expression 
levels were positively correlated with migration ability 
(Supplementary Fig. 1B), were also expressed moderately 
higher in selected highly migratory cells as compared 
with their parental cell lines (Supplementary Table 1, 
Supplementary Fig. 3). Increased expression of PAPPA in 
highly migratory cells was further validated by qRT-PCR 
(Fig. 2C). These observations strongly indicated that there 
is an inherent relationship between PAPPA expression and 
migration ability in MPM cells.
Major components of the IGF system are 
expressed in MPM cell lines
PAPPA has long been identified as a local regulator 
of IGF bioavailability through cleavage of IGFBP4 [10-
12], while IGF-1 has already been reported that it can 
induce MPM cell migration, a biological effect associated 
with IRS-2 phosphorylation [15]. We speculated that 
PAPPA may play a functional role in regulation of 
migration of MPM cells, at least partially, through the 
IGFBP-4/IGF-1/IGF-1R1 axis. Thus we characterized the 
major components of the IGF axis in MPM cell lines we 
used. IGF-1R expressions were detected at both mRNA 
and protein levels (Fig. 3A, 3B), which is consistent 
with previous report [23]. For IGF-1, no significant 
levels of secreted IGF-1 were detected by ELISA, and 
actually no mRNA of IGF1 was detected by qRT-PCR 
(data not shown). For IGFBPs, we examined the mRNA 
transcript profiles of IGFBP1 to 5 of MPM cells, notably, 
Oncotarget 2013; 4: 1172-11841174www.impactjournals.com/oncotarget
IGFBP3 and IGFBP4 were found to be the dominant 
IGF-1 binding proteins (Fig. 3C) expressed in MPM cell 
lines. We subsequently measured the concentrations of 
secreted IGFBP-3 (Fig. 3D) and IGFBP-4 (Fig. 3E) in 
the conditioned medium of MPM cell cultures. To test 
whether the PAPPA detected in the MPM cell conditioned 
medium is enzymatically active, we incubated rhIGFBP-4, 
rhIGF-1 with conditioned medium for 24 h, and subjected 
the conditioned medium to immunoblotting analysis. 
The conditioned medium of MPM cells did reveal 
enzymatic activity, as indicated by reduced rhIGFBP-4 
after incubation (Fig. 3F). And the enzymatic activity 
of the conditioned medium seems to be correlated with 
the concentrations of PAPPA in these medium (Fig. 3F, 
Fig. 1D). Since tissue plasminogen activator (tPA) was 
reported to have IGFBP-3 proteolytic activity [24], and 
we also detected that PLAT (gene encoding tPA protein) is 
expressed in MPM cell lines (Supplementary Fig. 1B), we 
performed an in vitro proteolysis analysis to see whether 
the enzymatic cleavage of IGFBP-4 of conditioned 
medium of MPM cells can also be attributed to tPA. It 
turned out that PAPPA revealed proteolytic activity of 
IGFBP-4 but not IGFBP-3, while tPA revealed proteolytic 
activity of IGFBP-3 but not IGFBP-4 (Fig. 3G), supporting 
the idea that PAPPA is specifically responsible for the 
IGFBP-4 proleolytic activity of MPM cell conditioned 
medium. Taken together, the major components of the IGF 
axis are expressed in MPM cells, which gives the context 
of functional role of PAPPA as local regulator of IGF-1 
for MPM cells.
Figure 1: Migration abilities of malignant pleural mesothelioma cells are positively correlated with their expression 
levels of PAPPA. A, The migration abilities of eight MPM cell lines determined by transwell migration assay, data are the means ± 
SEMs of three independent experiments. B, The expression levels of PAPPA in eight MPM cell lines determined by qRT-PCR. Data are 
representative of two independent assays carried out in triplicate (means ± SDs, n=3). C, The expression levels of PAPPA in eight MPM 
cell lines determined by qRT-PCR, were positively correlated with their migration ability. * P<0.05. The correlation efficient (r) and the 
significance (P) were calculated by Pearson’s correlation analysis. D, The concentrations of secreted PAPPA in the conditioned medium 
(48 h) were determined by ELISA. E, The concentrations of secreted PAPPA from MPM cells (D) tend to have positive correlation with 
their migration abilities. P=0.0671. The correlation efficient (r) and the significance (P) were calculated by Pearson’s correlation analysis.
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PAPPA enhanced migration of MPM cells by 
enzymatically cleaving inhibitive IGFBP-4 and 
releasing IGF-1 as chemotactic factor
To test the hypothesis that PAPPA could affect MPM 
cell migration via IGFBP-4/IGF-1/IGF-1R axis, a series 
of experiments were performed using transwell chamber 
assays with related recombinant proteins. Consistent with 
previous reports [15, 25], IGF-1 alone could stimulate the 
migration of EHMES-1 and MSTO-211H cells across a 
porous membrane in a dose-dependent manner (Fig. 4A, 
Fig. 4C). We also demonstrated that stimulating effect 
of IGF-1 could be blocked by IGFBP-4, while further 
addition of PAPPA would recover the stimulating effects 
of IGF-1 on MPM cell migration (Fig. 4B, Fig. 4D). 
PAPPA alone added to the lower chamber has no effects on 
cell migration (data not shown), excluding the possibility 
that the enhanced migration of MPM was due to the direct 
chemotactic effect of PAPPA. To further confirm that the 
released IGF-1, rather than the fragments of IGFBP-4 
generated by cleavage, recovered the enhanced cell 
migration, anti-IGF-1 antibody was used to neutralize 
the released IGF-1 from IGFBP-4 proteolysis caused by 
PAPPA. The enhanced cell migration was completely 
abrogated by anti-IGF-1 antibody (Fig. 4E). Taken 
together, our results suggest that PAPPA could enhance 
the migration of MPM cell via proteolysis of IGFBP-4 and 
subsequently releasing IGF-1 as chemotactic factor.
Silencing PAPPA by small interfering RNA 
inhibited migration and proliferation of MPM 
cells
To investigate the function of endogenous PAPPA 
on MPM cell migration more directly, we knocked down 
PAPPA in MPM cells (NCI-H290, MSTO-211H and 
EHMES-1) using siRNA and subsequently evaluated 
their migration ability. Efficacy of PAPPA silencing by 
siRNA were confirmed by qRT-PCR before the following 
functional assays (Fig. 5A). We found that PAPPA 
silencing significantly reduced cell migration (Fig. 5B). 
No difference of cell viability was observed at the time 
point of migration (24-30 h after siRNA treatment), 
as revealed by MTT assay (data not shown), but the 
inhibition of cell growth was also observed later, which 
became evident 72 h after PAPPA siRNA treatment (Fig. 
Figure 2: Selected highly migratory MPM cells and their PAPPA expression levels. A, Schematic representation of in vitro 
selection of highly migratory cells. B, The cells that went through in vitro selection process revealed higher migration ability (means ± 
SDs, n=3). Left, NCI-211H parental cell (211H) versus NCI-211 highly migratory cells (211HM). *** P<0.001, unpaired t test; middle, 
NCI-H290 parental cell (H290) versus NCI-H290 highly migratory cells (H290M). *** P<0.001, unpaired t test; right, Y-MESO-14 
parental cells (Y14) versus Y-MESO-14 highly migratory cells (Y14M). *** P<0.001, unpaired t test. C, The expression levels of PAPPA 
in selected cells were significantly higher as compared with that in parental cells. The data are representative of two independent assays 
carried out in triplicate (means ± SDs, n=3). Left, 211H versus 211HM. * P<0.05, unpaired t test; middle, H290 versus H290M, * P<0.05, 
unpaired t test; right, Y14 versus Y14M, * P<0.05, unpaired t test.
Oncotarget 2013; 4: 1172-11841176www.impactjournals.com/oncotarget
5C). These data confirmed the functional roles of PAPPA 
on the migration of MPM cells and revealed an extended 
role of PAPPA on the proliferation of these cells, indicating 
it might be directly used as therapeutic target to inhibit 
progression of MPM in vivo.
Figure 3: Characterization of major IGF components expression in MPM cell lines. A, Relative gene expression levels 
of IGF-1R in MPM cell lines assessed by qRT-PCR, normalized to the relative expression of IGF-1R in Y-MESO-5A cells. The data are 
representative of two independent assays carried out in triplicate (means ± SDs, n=3). B, IGF-1R1 expression detected by immunoblotting. 
C, Relative gene expression levels of IGFBPs in MPM cell lines characterized by qRT-PCR, normalized to that of ACTB. D, The 
concentrations of secreted IGFBP-3 in the conditioned medium (24 h) of MPM cells detected by ELISA. E, The concentrations of secreted 
IGFBP-4 in the conditioned medium (24 h) of MPM cells by ELISA. F, The conditioned medium of MPM cell lines revealed enzymatic 
activity of cleaving IGFBP-4. For the detection of IGFBP-4 proteolysis, rhIGFBP-4 (0.5 µg), rhIGF-1 (100 ng) were add into 50 µl 
conditioned medium of MPM cells and incubated for overnight at 37°C, then conditioned medium was subjected to immunoblotting 
analysis. G, The enzymatic activity of conditioned medium of mesothelioma cell lines. Left panel, rhIGF-1, rhIGFPB-4 was incubated with 
or without rhPAPPA for 24 h, and then subjected to immunoblotting analysis. rhPAPPA but not rhtPA revealed specific enzymatic activity 
of cleavage of IGFBP4. Right panel, rhtPA specifically cleaved rhIGFBP-3.
Oncotarget 2013; 4: 1172-11841177www.impactjournals.com/oncotarget
Transfection of PAPPA shRNA inhibited 
migration, invasion and proliferation of 
NCI-H290 cell line in vitro and tumor growth in 
orthotopic xenograft model
Our next series of experiments were aimed at 
further determining the phenotypic effects on MPM cells 
from PAPPA knockdown by establishing stable PAPPA 
knockdown cell lines. To establish stable cell line, we 
chose MPM cell line NCI-H290, which can be used to 
establish an orthotopic xenograft model of human MPM. 
This model reflects the clinical features of MPM patients, 
such as local tumor progression, malignant bloody pleural 
effusion in the pleural cavity [3-5, 26]. Silencing of PAPPA 
expression in cells transfected with PAPPA shRNA was 
confirmed (Fig. 6A) before carrying out following assays. 
Consistent with the results of transient knockdown of 
Figure 4: PAPPA enhances migration of MPM cells by enzymatically cleaving inhibitive IGFBP-4 and releasing IGF-
1 as chemotactic factor. A, rhIGF-1 induced migration of MSTO-211H cells in a dose-dependent manner. B, rhIGFBP-4 inhibited 
migration of MSTO-211H cells induced by rhIGF-1, while rhPAPPA recovered the ability of rhIGF-1 to induce migration of MSTO-211H. 
rhIGF-1 or rhIGF-1 + rhIGFBP-4 or rhIGF-1 + rhIGFBP4 + rhPAPPA were added in serum free medium and incubated at 37°C for 6 h 
before added into the lower chamber. C, rhIGF-1 attracted EHMES-1 cells to migrate dose-dependently. D, rhPAPPA recovered the ability 
of rhIGF-1 to induce the migration of EHMES-1 which was inhibited by rhIGFBP-4. E, An anti-IGF-1 antibody blocked the reversing 
effect of rhPAPPA on the migration of EHMES-1. Six-hours after the incubation with the rhIGF-1, rhIGFBP-4 and rhPAPPA mixture, an 
anti-IGF-1 antibody was added into the mixture and incubated for another 30 min before being added into the lower chambers. The data are 
representative of at least two independent assays carried out in triplicate (means ± SDs, n=3).* P<0.05, ** P<0.01, *** P<0.001, ns=not 
significant, one way ANOVA analysis.
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PAPPA by siRNA, migration ability of PAPPA shRNA cells 
was substantially reduced as compared to that of control 
shRNA cells (Fig. 6B). We also assessed the invasiveness 
of PAPPA shRNA cells using a Matrigel-coated transwell 
invasion assay. The decrease of invasiveness of PAPPA 
shRNA cells until 20-30% was even more profound than 
that of their migratory motility until 30-40% as compared 
to control shRNA cells (Fig. 6B, Fig. 6C). Also consistent 
with siRNA experiments, we observed a retardation of 
proliferation of PAPPA shRNA cells in vitro, as revealed 
by MTT assay (Fig. 6D). Despite of the growth retardation 
observed, the cells seem to be viable for a long time (for at 
least 14 days we followed) as assessed by morphological 
observation and Trypan blue exclusion test (data not 
shown).
Finally, we used a mouse orthotopic xenograft 
model to investigate the roles of PAPPA in MPM tumor 
progression in vivo. NCI-H290 cells stably transduced 
with PAPPA shRNA or control shRNA were orthotopically 
implanted into the pleural cavity of SCID mice. Mice were 
sacrificed 21-23 days after tumor cell inoculation. Control 
shRNA NCI-H290 developed tumors in the pleural cavity 
in all recipient mice at the time point of sacrifice, and 
showed classical patterns of diffusely grown pleural-
based masses. Four out of five mice developed bloody 
pleural effusions (hemothorax). On the other hand, PAPPA 
shRNA NCI-H290 only developed traces of tumor mass, 
and almost no pleural effusions were observed (Fig. 6E, 
Fig. 6F). Taken together, transfection of PAPPA shRNA in 
MPM cells confirmed the important role of PAPPA in cell 
migration, invasion and proliferation, further revealed its 
crucial role in MPM tumor development and progression 
in vivo.
DISCUSSION
In this study, we identified PAPPA as a migration-
promoting gene in MPM cell lines. By applying a novel 
approach of combination of transwell migration assay 
and microarray gene expression profiling, expression 
level of PAPPA is found to be correlated with migration 
ability of MPM cell lines. The correlation between 
PAPPA expression and migration ability in MPM was 
further supported by an in vitro selection strategy. PAPPA 
expression was found to be parallelly up-regulated in three 
migratory cell lines as compared to their corresponding 
parental cell lines. These results strongly suggested that 
PAPPA functionally promotes MPM cell migration.
The role of PAPPA as a local regulator of IGF 
bioavailability through cleavage of IGFBPs has been well 
documented [10-12], and the IGF axis was identified as 
one of the molecular networks involved in the formation, 
Figure 5: Effects of knockdown of PAPPA by siRNA on migration and proliferation of MPM cells. A, The expression of 
PAPPA in MPM cells (left, NCI-H290; middle, MSTO-211H; right, EHMES-1) was analyzed by qRT-PCR 24 h after transfection with 
siRNA targeting PAPPA. B, The migration ability of MPM cells (left, NCI-H290; middle, MSTO-211H; right, EHMES-1) were determined 
by transwell migration assay 24 h after transfection with siRNA targeting PAPPA. C, The proliferation of MPM cells (left, NCI-H290; 
middle, MSTO-211H; right, EHMES-1) was determined by MTT assay 72 h after transfection with siRNA targeting PAPPA. The data are 
representative of two independent assays carried out in triplicate (means ± SDs, n=3), * P<0.05, ** P<0.01, *** P<0.001, one way ANOVA 
analysis.
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progression and metastatic spread of many cancer 
types [13], including MPM [14-16, 27]. Based on this 
observation, we speculated that PAPPA could promote 
MPM cell migration via IGF-1. To set the stage for the 
functional role of PAPPA, we characterized the major 
components of the IGF axis in MPM cell lines. IGF-
1R and IGFBP1-5 were found to be expressed at varied 
levels in MPM cell lines. Our further experiments clearly 
demonstrated that the migration-promoting role can be 
explained by, at least partly, its proteolytic activity of 
IGFBP-4 to regulate the bioavailability of IGF-1. Previous 
studies showed the overexpression of IGF-1 in both MPM 
cell lines and tissues versus nonmalignant mesothelium 
at transcriptional level [14, 15], but we did not detected 
significant expression of IGF-1 at transcriptional 
level, which was consistent with another large-scale 
transcriptional profiling study of MPM [28]. The reason 
for this discrepancy among different reports remains to 
be determined, which might be explained by the variety 
of samples investigated. Despite of the discrepancy, 
given the fact that physiological ranges of serum IGF-
1 concentration [29] by far exceed the concentration of 
IGF-1 needed to have effects on MPM cell migration as 
demonstrated by us and others [15, 25], we believe that 
Figure 6: Effects of PAPPA shRNA transfection on migration, invasion, proliferation of NCI-H290 in vitro and 
tumor growth in orthotopic xenograft model. A, After transfection of PAPPA shRNA, gene silencing efficacy of PAPPA shRNA in 
NCI-H290 was confirmed by qRT-PCR.  *** P<0.001, unpaired t test. B, The migration ability of NCI-H290 cells transfected with PAPPA 
shRNA was significantly reduced as compared to that of cells transfected with nonsilencing control shRNA. The data are representative of 
two independent assays carried out in triplicate (means ± SDs, n=3), *** P<0.001, unpaired t test. C, The cell invasion through the Matrigel 
was significantly less in PAPPA shPAPPA transfected NCI-H290 cells as compared to that in cell transfected with control shRNA. The data 
are representative of two independent assays carried out in triplicate (means ± SDs, n=3), *** P<0.001, unpaired t test. D, The proliferation 
of PAPPA shRNA transfected cells was inhibited as compared to that of cells transfected with control shRNA. The data are representative of 
two independent assays carried out in triplicate (means ± SDs, n=3), *** P<0.001, unpaired t test. E, The effects of PAPPA shRNA on MPM 
tumor progression in the SCID mouse model of orthotopic xenograft. Pictures of the gross appearance of bloody pleural effusion (upper 
panel, white arrow) and tumor mass (lower panel, black arrow) of each group were shown. F, The qualitative analysis of pleural effusion 
(upper panel, ** P< 0.01, unpaired t test) and tumor mass (lower panel, *** P < 0.001, unpaired t test). 
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our experiments does have its physiological or even 
pathogenic relevance. It is worth noting that even though 
PAPPA did enhance MPM cell migration via IGFBP-4/
IGF-1 axis in our experimental setup, we did not exhaust 
the possibility that nonproteolytic mechanisms might be 
involved in the migration-promoting function of PAPPA.
In the present study, the functional role of PAPPA in 
MPM cell migration was investigated by gene silencing 
experiments using both siRNA and shRNA. Knockdown 
of PAPPA led to reduced MPM cell migration, invasion 
and proliferation. Exogenously addition of PAPPA could 
barely rescue the proliferation of MPM cells from the 
inhibitory effect of PAPPA silencing in vitro (data not 
shown). This implies that PAPPA might involve in an 
additional mechanism which has yet to be elucidated. 
In addition, NCI-H290 cells transfected with PAPPA 
shRNA, when inoculated into the pleural cavity of SCID 
mice, failed to develop tumors in vivo, while NCI-H290 
transfected with control shRNA developed massive tumors 
and bloody pleural effusions. These observations indicate 
that PAPPA facilitates the progression of MPM and that it 
might be a potential therapeutic target.
Accumulating evidences support the notion that 
PAPPA may play a role in cancer. PAPPA knockout mice 
were observed to have reduced incidence of spontaneous 
cancers [18]. A tumor growth-promoting role of PAPPA 
has been demonstrated in breast cancer [20] ovarian 
cancer [21] and lung cancer [22] with mouse models 
very recently. Even though the role of PAPPA in cancer 
has not gathered much attention, IGF-1, the pervasive 
growth factor whose local bioavailability it regulates, 
has long been an intense interest for cancer researchers 
[13]. Actually, several novel therapeutics aimed at the 
IGF-1/IGF-1R, particularly monoclonal antibodies and 
small molecule tyrosine kinase inhibitors are under 
clinical investigation [17]. A phase II clinical trial of 
cixutumumab, a monoclonal antibody to IGF-IR, which 
showed encouraging therapeutic efficacy for MPM 
in preclinical study [23], is currently ongoing for the 
treatment of patients with mesothelioma. Given the vital 
physiological function of IGF-1 axis, unforeseen enduring 
effects on metabolism, body fat, muscle mass, and bone 
density has been major concerns [17]. In contrast to the 
pervasive existence and versatile physiological functions 
of IGF-1 axis, PAPPA is barely expressed in adult tissues 
except placenta, cardiamyocyte and smooth muscle [30], 
and actually genetic deletion of PAPPA extended mean and 
maximum lifespan of by 30-40% in mice [19]. Therefore, 
PAPPA might serve as a better therapeutic target for MPM 
with more tumor specificity and less risks of side effects 
as compared to IGF-1 axis components as targets. Even 
though most of the studies on PAPPA so far suggested its 
tumor-promoting role is largely IGF-1-dependent, anti-
PAPPA therapy might provide therapeutic effects beyond 
the inhibition of the IGF-1/IGF-1R signaling axis. A recent 
study indicated that IGFBP-4 could inhibit angiogenesis 
both induced by IGF-1 and FGF-2 [31], Therfore, 
given the fact that the inhibition of PAPPA can lead to 
the stabilization of IGFBP-4, targeting PAPPA might 
provide extra therapeutic benefits due to angiogenesis 
inhibition via IGFBP-4/FGF-2 interaction. In addition, 
there are evidences showing that PAPPA could promote 
angiogenesis in the chick chorioallantoic membrane assay 
via a possible nonproteolytic mechanism [32], further 
supporting the idea that PAPPA is not simply an alternative 
target for IGF-1 axis, but a novel target might provide 
extra therapeutic effects. Actually our preliminary data 
implied that nonproteolytic mechanisms might be involved 
in the function of PAPPA in MPM cells (data not shown). 
Now we are trying to validate these preliminary findings 
and further investigate the mechanistic role of PAPPA in 
the pathogenesis of MPM.
To conclude, our results supported the idea that 
PAPPA can function as a migration-promoting gene in 
MPM cells, and revealed that its migration-promoting 
role could be partially explained by its proteolytic activity. 
Given the fact that knockdown of PAPPA affected cell 
functions including cell migration in vitro and tumor 
development in vivo, we propose that it might be used a 
novel therapeutic target for the treatment of MPM.
METHODS
Cell culture
The human MPM cell lines, MSTO-211H, 
NCI-H2052, NCI-H2373, NCI-H2452 and NCI-H28, 
were purchased from the American Type Culture 
Collection (Manassas, VA). The human MPM cell lines, 
NCI-H290 and EHMES-1, were kindly provided by Dr. 
Adi F. Gazdar (University of Texas South-western Medical 
Center, Dallas, TX) and Dr. Hironobu Hamada (Ehime 
University, Toon, Japan), respectively. The human MPM 
cell lines, Y-MESO-14 and Y-MESO-5A, were established 
as described previously [33]. These MPM cell lines were 
maintained in RPMI1640 (Nissui Pharmaceutical, Tokyo, 
Japan) supplemented with 10% heat-inactivated fetal 
bovine serum (GIBCO, Grand Island, NY), penicillin 
(100 U/ml), and streptomycin (50 μg/ml). All cell lines 
were incubated at 37°C in a humidified atmosphere of 5% 
CO2. Cell lines were authenticated by DNA fingerprinting 
[34].
Migration and invasion assay 
Cell migration was determined by using 24-well 
transwell chambers with polycarbonate membranes (8.0-
μm pore size; BD Biosciences, Bedford, MA). Human 
MPM cell suspensions in serum free medium were added 
to the upper chamber at 1 × 105 cells per well. RPMI-
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1640 culture medium with or without 10% FBS were 
added in the lower well, and the cells were allowed to 
migrate for 6 h at 37°C in CO2 incubator. Nonmigrant 
cells were removed from the upper face of the membrane 
with a cotton swab. The cells were then fixed and stained 
with Qiff-Quik Staining Kit (Sysmex, Kobe, Japan). The 
membranes were excised from the chamber and mounted. 
The migrant cells attached to the lower face of the 
membrane were counted. For in vitro selection of highly 
migratory cells, we used a method as descripted previously 
[35]. Briefly, instead of fixing and staining the migrated 
cells on the lower face of membrane as a routine process, 
the migrated cells were detached by trypsin treatment, then 
collected, cultured and propagated. The propagated cells 
were again subjected to transwell migration assay, and 
this process was repeated for 3-5 times. Cell Invasion was 
determined by using Matrigel-coated transwell chambers 
(BD Biosciences, Bedford, MA) according to protocols 
similar to that of migration assay except that allowing the 
cell to migrate for longer time (18 h).
RNA isolation and quantitative RT-PCR
Total cellular RNAs were isolated using RNeasy 
Mini Kit (Qiagen, Valencia, CA). After quantification 
and verification for purity (optical density 260/280 ratios 
between 1.8 and 2.0) with NanoDrop 1000 (Thermo 
Scientific, Yokohama, Japan), RNA was reversely 
transcribed with Takara PCR thermal cycler Dice (Takara 
Bio, Kyoto, Japan) using High Capacity RNA-to-cDNA 
Kit (Applied Biosystems, Foster City, CA) following the 
manufacturer’s instruction. Subsequent quantitative RT-
PCR was carried out with CFX96 real-time PCR system 
(Bio-Rad, Hercules, CA) using Applied Biosystems’ 
Taqman gene expression assays for PAPPA (Hs01032307_
m1), IGFR1 (Hs00609566_m1), IGF1 (Hs01547656_m1), 
IGFBP1 (Hs00236877_m1), IGFBP2 (Hs01040719_m1), 
IGFBP3 (Hs00365742_g1), IGFBP4 (Hs01057900_m1), 
IGFBP5 (Hs00181213_m1). Samples were normalized 
to GAPDH (Hs99999905_m1) or ACTB (Hs99999903_
m1) and quantification was determined by using the 
ΔΔCT method.
Microarray analysis
Total RNA from MPM cells was isolated using an 
RNeasy Mini kit (QIAGEN, Valencia, CA). RNA quality 
was first checked for chemical purity using a NanoDrop 
spectrophotomer (NanoDrop Technologies, Wilmington, 
DE) and then assessed for RNA integrity using the 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, 
CA, USA). One hundred ng of total RNA was amplified 
and labeled using the Affymetrix Whole-Transcript 
(WT) Sense Target Labeling Protocol, and labeled RNA 
was hybridized to GeneChip Human Gene 1.0 ST Array 
(Affymetrix, Santa Clara, CA). Data visualization and 
analysis was performed using GeneSpring GX (Version 
12.1) software.
ELISA
The human MPM cells (2 × 105) were cultured in 
medium described above for 24 h, washed with phosphate 
buffered saline (PBS), 3 ml of fresh culture medium or 
serum free culture medium were added. After incubation 
for 24 or 48 h, the culture media were harvested 
and centrifuged, and the supernatants were stored at 
−70°C until analysis. Protein levels in supernatants 
were quantified by ELISA kit for human IGFBP-3, 
PAPPA (R&D systems, Minneapolis, MN), IGFBP-4 
(Abcam, Cambridge, MA) following the manufacturers’ 
instructions.
Immunoblotting analysis
For the detection of IGFR1 expression in cell 
lines, the cells were lysed in M-PER (Pierce, Rockford, 
IL) containing phosphatase and proteinase inhibitor 
cocktails (Roche, Indianapolis, IN). The concentrations 
of protein were determined using Bio-Rad Protein Assay 
Kit (Bio-Rad, Hercules, CA). Blots were incubated with 
antibodies: IGFR1 (diluted 1:500, 111A9, Cell Signaling, 
Danvers, MA), β-actin (diluted1:5000, I-19, Santa Cruz 
Biotechnology, Santa Cruz, CA) overnight. For the 
detection of IGFBP-4 proteolysis, rhIGF-1, rhIGFBP-4, 
rhPAPPA and rhtPA (R&D systems, Minneapolis, MN) 
were incubated at the indicated concentration in 50 
mM Tris, 10 mM CaCl2, 150 mM NaCl, pH 7.5 buffer 
for 6 h or overnight at 37°C. Protein mixture was 
transferred to iBlotTM gel Tranfer Stacker polyvinylidene 
difluoride (PVDF) membrane (Invitrogen, Carlsbad, CA) 
according to manufacturer’s instruction, the membranes 
were incubated at room temperature for 2 h with anti-
IGFBP-4 (K13RE) antibody (diluted 1:1000, Santa 
Cruz Biotechnology, Santa Cruz, CA). All analysis were 
revealed using the horseradish peroxidase(HRP)-labeled 
anti-rabbit or anti-mouse antibodies (GE Healthcare, 
Tokyo, Japan), and visualized using SuperSignal West 
Femto Maximum Sensitivity Substrate (Thermo Scientific, 
Yokohama, Japan) with a quantitative imaging system 
LAS4000Mini (Fujifilm, Tokyo, Japan).
In vitro siRNA transfection
Stealth RNAi™ siRNA for PAPPA (HSS107591, 
HSS181743; Invitrogen, Carlsbad, CA) transfection was 
conducted with Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA) following the manufacture’s protocol. Gene knock 
down efficacy was confirmed by qRT-PCR at the time 
Oncotarget 2013; 4: 1172-11841182www.impactjournals.com/oncotarget
points of 24, 48, and 72 h. The resultant cells were used 
for biological assays at the indicated time point after 
siRNA transfection. Stealth RNAi™ siRNA Negative 
Control Med GC Duplex (Invitrogen, Carlsbad, CA) was 
used as negative control throughout the experiment.
Lentivirus and infections
MISSION shRNA pLKO.1 constructs (Sigma-
Aldrich, St. Louis, MO) were used to make self-
inactivating shRNA lentivirus for PAPPA [sequence 5’-
CCG GGG TGA CGG ATG GGA CAT ATT ACT CGA 
GTA ATA TGT CCC ATC CGT CAC CTT TTT TG-3’ 
(clone NM_002581.3-3690s21c1)], and a non-target 
random scrambled sequence control (SHC002). For virus 
transduction, 2 × 106 NCI-H290 cells were incubated 
with lentivirus plus 5 µg/ml polybrene (CHEMICON 
International, Temecula, CA) for 24 h. The successfully 
transduced clones were identified by puromycin (Sigma-
Aldrich, St. Louis, MO) selection.
MTT assay
Cell proliferation was measured by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dye reduction method [26]. Briefly, 
the MPM cells (2 × 103/well) were seeded in 96-well 
plates and cultured for 72 h. After incubation, 50 µl of 
stock MTT solution (2 mg/ml; Sigma, St. Louis, MO) 
was added to each well, and the cells were then further 
incubated for 2 h. The media containing MTT solution 
were removed and the dark blue crystals were dissolved by 
adding 100 µl of DMSO. Absorbance was measured with 
a Sunrise Microplate Reader (Tecan Group, Männedorf, 
Switzerland) at test and reference wavelengths of 550 and 
620 nm, respectively.
Orthotopic xenograft mouse model
Male severe combined immunodeficiency (SCID) 
mice aged 6-7 weeks (CLEA Japan, Osaka, Japan) were 
maintained under specific pathogen-free conditions 
throughout the study. Ethics approval for all animal 
experiments was obtained from Animal Care and Use 
Committee of The University of Tokushima. An orthotopic 
implantation model of human MPM was established as 
described previously [3-5, 26]. Briefly, 3 × 105 NCI-H290 
cells in 100 µl of PBS were injected into the right pleural 
cavity of mice. The mice were sacrificed 21-23 days after 
tumor inoculation. The pleural tumors were carefully 
dissected and weighed; the pleural effusion was harvested 
using a 1-ml syringe, and the volume of the pleural 
effusion was measured.
Statistical analysis
The statistical significances of the differences 
were analyzed by Student’s t test, one way ANOVA 
analysis, where applicable. The correlation efficient and 
the significance were calculated by Pearson’s correlation 
analysis. The P-values less than 0.05 were considered 
significant in all experiments. Data analysis was carried 
out using GraphPad Prism version 5.01 (GraphPad 
Software, La Jolla, CA).
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